Tag Archives: MYGN

A Director at Myriad Genetics (NASDAQ: MYGN) is Buying Shares

Today, a Director at Myriad Genetics (MYGN – Research Report), John Henderson, bought shares of MYGN for $164.2K. Following this transaction John Henderson’s holding in the company was increased by 2333.33% to a total of $1.54 million. See today’s analyst

Myriad Genetics (MYGN) Receives a Hold from Needham

In a report released today, Stephen Unger from Needham maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The company’s shares closed last Monday at $35.10. According to TipRanks.com, Unger is a 4-star analyst with an average return

Myriad Genetics (MYGN) Receives a Sell from Barclays

In a report released yesterday, Jack Meehan from Barclays maintained a Sell rating on Myriad Genetics (MYGN – Research Report), with a price target of $22. The company’s shares closed last Monday at $22.97, close to its 52-week low of

Barclays Keeps Their Sell Rating on Myriad Genetics (MYGN)

Barclays analyst Jack Meehan maintained a Sell rating on Myriad Genetics (MYGN – Research Report) today and set a price target of $21. The company’s shares opened today at $29.24, close to its 52-week low of $26.80. According to TipRanks.com,

Merrill Lynch Keeps a Sell Rating on Myriad Genetics (MYGN)

Merrill Lynch analyst Derik De Bruin maintained a Sell rating on Myriad Genetics (NASDAQ: MYGN) today and set a price target of $34. The company’s shares opened today at $43.50. According to TipRanks.com, Bruin is a 3-star analyst with an

Morgan Stanley Believes Myriad Genetics (NASDAQ: MYGN) Won’t Stop Here

In a report released today, Steve Beuchaw from Morgan Stanley maintained a Buy rating on Myriad Genetics (NASDAQ: MYGN), with a price target of $49. The company’s shares closed yesterday at $42.84, close to its 52-week high of $44.87. According